Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -485.73%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-485.73%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ensysce Biosciences, Inc.
Market Cap
$6.44M
EBITDA Margin
-485.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.34M
EBITDA Margin
-110.02%
TTM Avg
-99.60%
3Y Avg
-109.65%
5Y Avg
-93.07%
Market Cap
$6.72M
EBITDA Margin
-430.70%
TTM Avg
-678.73%
3Y Avg
-962.21%
5Y Avg
-5357.45%
Market Cap
$6.74M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
Market Cap
$6.76M
EBITDA Margin
-10.17%
TTM Avg
-10.02%
3Y Avg
-12.29%
5Y Avg
-11.98%
Market Cap
$6.10M
EBITDA Margin
-729.87%
TTM Avg
-884.05%
3Y Avg
-981.20%
5Y Avg
-851.95%
Market Cap
$6.10M
EBITDA Margin
-41051.94%
TTM Avg
-32118.88%
3Y Avg
-145781.05%
5Y Avg
-130042.11%
Market Cap
$6.09M
EBITDA Margin
-417.17%
TTM Avg
-417.17%
3Y Avg
-417.17%
5Y Avg
-417.17%
Market Cap
$6.03M
EBITDA Margin
-9081.41%
TTM Avg
-6199.48%
3Y Avg
-3862.58%
5Y Avg
-3269.64%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.44M | -485.73% | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -110.02% | -99.60% | -109.65% | -93.07% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -430.70% | -678.73% | -962.21% | -5357.45% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -10.17% | -10.02% | -12.29% | -11.98% |
| Femasys Inc. (FEMY)vs › | $6.10M | -729.87% | -884.05% | -981.20% | -851.95% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -41051.94% | -32118.88% | -145781.05% | -130042.11% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | -417.17% | -417.17% | -417.17% | -417.17% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -9081.41% | -6199.48% | -3862.58% | -3269.64% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -4847.72% | -2918.14% | -1630.06% | -1069.46% |
Gross Margin
0.0%
EBITDA Margin
-485.7%
Operating Margin
0.0%
Net Margin
-1084.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -221.28% |
| 2020-03-31 | -29.48% |
